Martin Plöderl
@ploederl.bsky.social
Clinical psychologist and psychotherapist, part-time researcher with a focus on suicide prevention and psychopharmacology.
https://ploederlm.github.io/publications/
https://scholar.google.at/citations?user=76cO6AEAAAAJ&hl=de
Nature, espresso, cycling.
https://ploederlm.github.io/publications/
https://scholar.google.at/citations?user=76cO6AEAAAAJ&hl=de
Nature, espresso, cycling.
New method to estimate heterogeneity of treatment effects by comparing the cumulative response distributions for the treatment vs.
www.sciencedirect.com/science/arti...
@f2harrell.bsky.social @stephensenn.bsky.social
www.sciencedirect.com/science/arti...
@f2harrell.bsky.social @stephensenn.bsky.social
November 12, 2025 at 7:49 AM
New method to estimate heterogeneity of treatment effects by comparing the cumulative response distributions for the treatment vs.
www.sciencedirect.com/science/arti...
@f2harrell.bsky.social @stephensenn.bsky.social
www.sciencedirect.com/science/arti...
@f2harrell.bsky.social @stephensenn.bsky.social
One more picture from this week's early frosty morning bike ride, with thd full moon descending
November 8, 2025 at 10:43 AM
One more picture from this week's early frosty morning bike ride, with thd full moon descending
Full moon and rest of fog on my early morning bike ride
November 6, 2025 at 6:08 AM
Full moon and rest of fog on my early morning bike ride
Stars, moon, autumn sky
November 3, 2025 at 5:23 PM
Stars, moon, autumn sky
@ianhussey.mmmdata.io
This trial might be worth looking at. I have never seen such a trajectory of symptoms in the medication group. Some other red flags, too.
This trial might be worth looking at. I have never seen such a trajectory of symptoms in the medication group. Some other red flags, too.
November 2, 2025 at 4:24 PM
@ianhussey.mmmdata.io
This trial might be worth looking at. I have never seen such a trajectory of symptoms in the medication group. Some other red flags, too.
This trial might be worth looking at. I have never seen such a trajectory of symptoms in the medication group. Some other red flags, too.
October 27, 2025 at 3:39 PM
Ah, it's in the supplement. Interesting! Even no short-term effects!
October 22, 2025 at 7:11 PM
Ah, it's in the supplement. Interesting! Even no short-term effects!
Call for abstracts is open for the European Symposium on Suicide and Suicidal Behavior, ESSSB21 (Vilnius, 26-29 August 2026). Submit your symposium, workshop, oral, or poster by the deadlines. Details: www.esssb21.org/call-for-pap...
October 20, 2025 at 9:03 AM
Call for abstracts is open for the European Symposium on Suicide and Suicidal Behavior, ESSSB21 (Vilnius, 26-29 August 2026). Submit your symposium, workshop, oral, or poster by the deadlines. Details: www.esssb21.org/call-for-pap...
Perfect weather for cows
October 18, 2025 at 1:33 PM
Perfect weather for cows
Diese Art von Täuschungen sollten verboten werden
(Anm: ich habe das nicht gekauft)
(Anm: ich habe das nicht gekauft)
October 11, 2025 at 8:14 AM
Diese Art von Täuschungen sollten verboten werden
(Anm: ich habe das nicht gekauft)
(Anm: ich habe das nicht gekauft)
How may the "Big Beautiful Bill" and associated cuts in financial support for not so wealthy people in the US impact suicide rates?
I summarized the excellent talk by Stephen Stack and put it into the current context (German).
Here's a link to the talk by Stack
www.youtube.com/watch?v=xIg1...
I summarized the excellent talk by Stephen Stack and put it into the current context (German).
Here's a link to the talk by Stack
www.youtube.com/watch?v=xIg1...
October 3, 2025 at 7:02 AM
How may the "Big Beautiful Bill" and associated cuts in financial support for not so wealthy people in the US impact suicide rates?
I summarized the excellent talk by Stephen Stack and put it into the current context (German).
Here's a link to the talk by Stack
www.youtube.com/watch?v=xIg1...
I summarized the excellent talk by Stephen Stack and put it into the current context (German).
Here's a link to the talk by Stack
www.youtube.com/watch?v=xIg1...
Call for Abstracts:
www.esssb21.org/call-for-pap...
www.esssb21.org/call-for-pap...
September 30, 2025 at 7:32 AM
Call for Abstracts:
www.esssb21.org/call-for-pap...
www.esssb21.org/call-for-pap...
🚨 Announcement of the 21st European Symposium on Suicide and Suicidal Behaviour, August 26-29 2026, Vilnuis
www.esssb21.org
www.esssb21.org
September 30, 2025 at 7:30 AM
🚨 Announcement of the 21st European Symposium on Suicide and Suicidal Behaviour, August 26-29 2026, Vilnuis
www.esssb21.org
www.esssb21.org
12/ So we aimed at explaining the discrepancies. In a first attempt we did our own pairwise meta-analysis and found that efficacy estimates for fluoxetine reduced over time, see figure with the meta-analytic aggregation of efficacy over time (gray shaded area)
September 26, 2025 at 5:00 AM
12/ So we aimed at explaining the discrepancies. In a first attempt we did our own pairwise meta-analysis and found that efficacy estimates for fluoxetine reduced over time, see figure with the meta-analytic aggregation of efficacy over time (gray shaded area)
7/ For background, they used the Childhood Depression Rating Scale CDRS-R (range 17 to 113) as outcome, and the area of equivalence was +/- 5 points. This can be transformed to a SMD with their suggested standard deviation. Here the results:
September 26, 2025 at 5:00 AM
7/ For background, they used the Childhood Depression Rating Scale CDRS-R (range 17 to 113) as outcome, and the area of equivalence was +/- 5 points. This can be transformed to a SMD with their suggested standard deviation. Here the results:
5/ With GRADE, the confidence in the evidence for fluoxetine vs placebo comparisons was rated as “very low” in both NMAs. Unfortunately, this important information was not mentioned in guideline recommendations that we are aware of.
September 26, 2025 at 5:00 AM
5/ With GRADE, the confidence in the evidence for fluoxetine vs placebo comparisons was rated as “very low” in both NMAs. Unfortunately, this important information was not mentioned in guideline recommendations that we are aware of.
1/32 Fluoxetine's loss of efficacy for the treatment of pediatric depression.
🚨 New paper and pre-print alert 🚨
With great colleagues @floriannaudet.bsky.social @richlyus.bsky.social @markhoro.bsky.social @joannamoncrieff.bsky.social and Gert van Valkenhoef
A longer 🧵
🚨 New paper and pre-print alert 🚨
With great colleagues @floriannaudet.bsky.social @richlyus.bsky.social @markhoro.bsky.social @joannamoncrieff.bsky.social and Gert van Valkenhoef
A longer 🧵
September 26, 2025 at 5:00 AM
1/32 Fluoxetine's loss of efficacy for the treatment of pediatric depression.
🚨 New paper and pre-print alert 🚨
With great colleagues @floriannaudet.bsky.social @richlyus.bsky.social @markhoro.bsky.social @joannamoncrieff.bsky.social and Gert van Valkenhoef
A longer 🧵
🚨 New paper and pre-print alert 🚨
With great colleagues @floriannaudet.bsky.social @richlyus.bsky.social @markhoro.bsky.social @joannamoncrieff.bsky.social and Gert van Valkenhoef
A longer 🧵
Coming soon as paper, available as preprint, and currently presented at the RCP conference by @richlyus.bsky.social
Will do a thread soon
Will do a thread soon
September 25, 2025 at 2:58 PM
Coming soon as paper, available as preprint, and currently presented at the RCP conference by @richlyus.bsky.social
Will do a thread soon
Will do a thread soon
No COIs declared in this paper, but this can be found in another paper of the author:
September 16, 2025 at 11:19 AM
No COIs declared in this paper, but this can be found in another paper of the author:
Why it may be important to declare the COI:
(from this journal)
(from this journal)
September 16, 2025 at 11:13 AM
Why it may be important to declare the COI:
(from this journal)
(from this journal)
Antidepressant prescription rates in the US up to 2023, based on the Medical Expenditure Panel Survey.
Now 12% of the US-population used an antidepressant in 2023, which is an all-time-record.
Now 12% of the US-population used an antidepressant in 2023, which is an all-time-record.
September 16, 2025 at 8:32 AM
Antidepressant prescription rates in the US up to 2023, based on the Medical Expenditure Panel Survey.
Now 12% of the US-population used an antidepressant in 2023, which is an all-time-record.
Now 12% of the US-population used an antidepressant in 2023, which is an all-time-record.
2/ When in fact suicidal behavior occurred more often with fluoxetine versus placebo or CBT, as shown in a recent RIAT-reanalysis
journals.sagepub.com/doi/epub/10....
journals.sagepub.com/doi/epub/10....
September 15, 2025 at 6:53 AM
2/ When in fact suicidal behavior occurred more often with fluoxetine versus placebo or CBT, as shown in a recent RIAT-reanalysis
journals.sagepub.com/doi/epub/10....
journals.sagepub.com/doi/epub/10....
3/ However, according to a publication from about the same time, the senior author declared the following (see screenshot) - these are massive COIs!
psychiatryonline.org/doi/pdf/10.1...
psychiatryonline.org/doi/pdf/10.1...
September 15, 2025 at 5:50 AM
3/ However, according to a publication from about the same time, the senior author declared the following (see screenshot) - these are massive COIs!
psychiatryonline.org/doi/pdf/10.1...
psychiatryonline.org/doi/pdf/10.1...
From the Abiri trial: they say that the variation are SDs but the SD is very small for the change-scores. The SMD based on endpoint scores is only -0.07 (-0.62 - 0.47, my calc.). The SMD based on change-score is -1.52 (-2.15 to -0.89). Likely the "standard error"!
www.tandfonline.com/doi/abs/10.1...
www.tandfonline.com/doi/abs/10.1...
September 8, 2025 at 8:11 AM
From the Abiri trial: they say that the variation are SDs but the SD is very small for the change-scores. The SMD based on endpoint scores is only -0.07 (-0.62 - 0.47, my calc.). The SMD based on change-score is -1.52 (-2.15 to -0.89). Likely the "standard error"!
www.tandfonline.com/doi/abs/10.1...
www.tandfonline.com/doi/abs/10.1...